Tevogen (TVGN) Bio Holdings announced it has received the previously reported $1M in funding to advance Tevogen.AI. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in nondilutive funding. KRHP LLC is affiliated with an existing Tevogen investor. Following Tevogen.AI’s recent announcement of the patent publication of its proprietary machine learning technology for predicting immunologically active peptides, the Company plans to use the funding to accelerate Tevogen.AI’s capabilities, enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen expanding collaboration with Microsoft and Databricks
- Tevogen signs letter of intent for new cell therapy manufacturing facility
- AI Daily: OpenAI said to end acquisition talks with Windsurf
- Tevogen.AI builds alpha version of PredicTcell model
- Tevogen Bio Grants Restricted Stock to CEO